Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
The News Review:
- Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
- Pleiad Devices Selects mniComm Systems as their eClinical …
- Research and Markets: Clinical Research Manual: International …
- » Clinical Research Associate
- NIAID to ffer $100M for Immune System Research Centers
- Encorium Reports Second Quarter 2009 Financial Results
- CCA Focus: Insulin Resistance in Diabetes and Cardiovascular Disease
Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
PR Newswire (press release)
We operate under the concept of DATATRAK NE(TM) which encompasses our unique single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through an integrated multi-component comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK’s eClinical((TM)) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International Inc. ’s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies.
Pleiad Devices Selects mniComm Systems as their eClinical …
PR Newswire (press release)
“We are pleased to once again be collaborating with Pleiad as the exposure generated from working closely on a continual basis with such a specialized internationally renowned CR will undoubtedly raise our profile within the international clinical community” commented Stephen Johnson mniComm’s C. “We expect that as we continue to work with well respected high profile organizations such as Pleiad we will continue to attract companies of an equally high caliber to our dramatically enhanced service offering. We feel that we can offer organizations engaged in clinical research a significant advantage over their peers with our highly specialized portfolio of eClinical solutions designed to greatly simplify the clinical process. ” “TrialMaster has been an essential option for us to provide to our customers. Much is made about the importance of subject compliance in clinical research but we find that study coordinator ‘compliance’ is also very critical. The TrialMaster EDC system is very intuitive so the study coordinators with whom we work have little problem in getting their work completed within the allocated time” stated Stephen Brandao Pleiad’s Vice President of Business Development. “We find that mniComm is an attentive partner very much in tune with the needs of our business.
Research and Markets: Clinical Research Manual: International …
Business Wire (press release)
A practical annually updated international handbook for all those working in clinical research. The editors have a wealth of experience between them of the teaching and practice of clinical research and have selected and reviewed each chapter to ensure completeness and relevance.
» Clinical Research Associate
Hays Pharma
00 per annumLocationBulgaria25 Aug 2009ur client a global CR is looking for Clinical Research Associates in Bulgaria. DescriptionThe responsibility of a Clinical Research Associate is to perform the clinical monitoring aspect of designated projects in accordance with my client's SPs. lapadatu@hayspharma.
NIAID to ffer $100M for Immune System Research Centers
GenomeWeb Daily News
These studies will exploit recent scientific advances in systems biology integrating information about an organism’s genes proteins and metabolism with data from the host NIAID said. “The observations made and the new methodologies developed by investigators within this program will assist clinical research in vaccine development and beyond” NIAID’s Director of the Division of Allergy Immunology and Transplantation Daniel Rotrosen said. “These research centers are part of NIAID’s long-range goal to identify the principles of human immune regulation and then apply that knowledge to understanding treating and preventing immune-mediated and infectious diseases. ” Related Stories$4M NIH Grant Supports Synchrotron Work in Protein Structure Proteomics and Life Sciences.
Encorium Reports Second Quarter 2009 Financial Results
PR Newswire (press release)
About Encorium Group Inc. Encorium Group Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical biotechnology and medical device industries. The Company’s mission is to provide its clients with high quality full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise experienced team management and advanced technologies. Encorium believes that its expertise in the design of complex clinical trials its therapeutic experience and commitment to excellence and its application of innovative technologies offer its clients a means to more quickly and cost effectively move products through the clinical development process.
CCA Focus: Insulin Resistance in Diabetes and Cardiovascular Disease
Cardiosource
Suzanne Hughes: I know you have a very strong background as a nurse practitioner in the field of preventive cardiology. For the last several years along with working in a clinical setting you have worked in a research environment studying insulin resistance. How is this work different for you? And what have you learned in studying insulin resistance that is applicable to the field of cardiovascular risk reduction? Cindy Lamendola: Well even in clinical research there is always an opportunity for patient education and now my focus not only includes cardiovascular risk factors and prevention but also insulin resistance prediabetes and the different mechanisms that lead up to cardiovascular disease and type 2 diabetes and other clinical outcomes. The best part of being involved in research is just that—there are so many opportunities to look at mechanisms that influence different clinical outcomes. In the past 12 years of working in research on insulin resistance we have seen the consequences of insulin resistance grow from prediabetes diabetes and cardiovascular risk factors that increase risk for cardiovascular disease to now include: polycystic ovary syndrome nonalcoholic fatty liver disease obstructive sleep apnea and schizophrenia as well as other possible outcomes such as some type of cancers and cardiomyopathy. We now know that when we see patients with these other medical problems they may also be at increased risk for type 2 diabetes and heart disease. 1SH: How exactly is insulin resistance measured?CL: Currently the gold standard is by doing a test called a Euglycemic CLAMP or an insulin sensitivity test.
Related from Medcylopaedia: Type 2 diabetics more susceptible to dementia
Written by admin on August 25th, 2009 with
no comments.
Read more articles on News.